AEON Biopharma Responds to Recent Court Ruling

IRVINE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, responded today to the recent ruling by the Seoul Central District Court in favor of Medytox, Inc. related to a lawsuit over patent infringement.

Development Strategy Unaffected

Despite the court ruling in favor of Medytox, AEON Biopharma has confirmed that the development strategy and timelines for ABP-450, their proprietary botulinum toxin complex, remain unaffected. The company remains committed to advancing research and development in the field of biopharmaceuticals for the treatment of various medical conditions.

Impact on Individuals

For individuals who may be affected by medical conditions that could potentially be treated by ABP-450 in the future, the confirmation of AEON Biopharma’s development strategy is reassuring. It signals continued progress towards potential new treatment options that could improve quality of life for those suffering from debilitating medical conditions.

Global Implications

The unaffected development strategy of AEON Biopharma following the court ruling has broader implications for the biopharmaceutical industry worldwide. It demonstrates the company’s resilience and commitment to innovation in the face of legal challenges, potentially setting a precedent for other companies facing similar obstacles.

Conclusion

In conclusion, AEON Biopharma’s confirmation of their development strategy and timelines for ABP-450 in light of the recent court ruling showcases their dedication to advancing research and development in the field of biopharmaceuticals. This steadfast commitment has the potential to benefit individuals in need of new treatment options, as well as the broader global biopharmaceutical industry.